|
|||||||
|
Fusion Protein:ACACA-CCL5 |
Fusion Gene and Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: ACACA-CCL5 | FusionPDB ID: 1144 | FusionGDB2.0 ID: 1144 | Hgene | Tgene | Gene symbol | ACACA | CCL5 | Gene ID | 31 | 6352 |
| Gene name | acetyl-CoA carboxylase alpha | C-C motif chemokine ligand 5 | |
| Synonyms | ACAC|ACACAD|ACC|ACC1|ACCA | D17S136E|RANTES|SCYA5|SIS-delta|SISd|TCP228|eoCP | |
| Cytomap | 17q12 | 17q12 | |
| Type of gene | protein-coding | protein-coding | |
| Description | acetyl-CoA carboxylase 1ACC-alphaacetyl-Coenzyme A carboxylase alpha | C-C motif chemokine 5T-cell specific protein p288beta-chemokine RANTESchemokine (C-C motif) ligand 5eosinophil chemotactic cytokineregulated upon activation, normally T-expressed, and presumably secretedsmall inducible cytokine subfamily A (Cys-Cys) | |
| Modification date | 20200313 | 20200313 | |
| UniProtAcc | Q13085 Main function of 5'-partner protein: FUNCTION: Cytosolic enzyme that catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the first and rate-limiting step of de novo fatty acid biosynthesis (PubMed:20952656, PubMed:20457939, PubMed:29899443). This is a 2 steps reaction starting with the ATP-dependent carboxylation of the biotin carried by the biotin carboxyl carrier (BCC) domain followed by the transfer of the carboxyl group from carboxylated biotin to acetyl-CoA (PubMed:20952656, PubMed:20457939, PubMed:29899443). {ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656, ECO:0000269|PubMed:29899443}. | P13501 Main function of 5'-partner protein: FUNCTION: Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form RANTES(3-68) acts as a natural chemotaxis inhibitor and is a more potent inhibitor of HIV-1-infection. The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) and is generated by an unidentified enzyme associated with monocytes and neutrophils (PubMed:16791620, PubMed:1380064, PubMed:8525373, PubMed:9516414, PubMed:15923218). May also be an agonist of the G protein-coupled receptor GPR75, stimulating inositol trisphosphate production and calcium mobilization through its activation. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells (PubMed:23979485). {ECO:0000269|PubMed:1380064, ECO:0000269|PubMed:15923218, ECO:0000269|PubMed:16791620, ECO:0000269|PubMed:17001303, ECO:0000269|PubMed:23979485, ECO:0000269|PubMed:8525373, ECO:0000269|PubMed:9516414}. | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000335166, ENST00000394406, ENST00000353139, ENST00000360679, ENST00000361253, ENST00000416895, ENST00000588142, ENST00000589665, | ENST00000293272, ENST00000366113, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 44 X 35 X 17=26180 | 2 X 2 X 2=8 |
| # samples | 51 | 3 | |
| ** MAII score | log2(51/26180*10)=-5.68182403997375 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(3/8*10)=1.90689059560852 | |
| Fusion gene context | PubMed: ACACA [Title/Abstract] AND CCL5 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Fusion neoantigen context | PubMed: ACACA [Title/Abstract] AND CCL5 [Title/Abstract] AND neoantigen [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | ACACA(35478277)-CCL5(34199468), # samples:1 ACACA(35478276)-CCL5(34199468), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | ACACA-CCL5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ACACA-CCL5 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ACACA-CCL5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ACACA-CCL5 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ACACA-CCL5 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF. ACACA-CCL5 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. ACACA-CCL5 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | CCL5 | GO:0006816 | calcium ion transport | 10734056 |
| Tgene | CCL5 | GO:0006874 | cellular calcium ion homeostasis | 10734056 |
| Tgene | CCL5 | GO:0006887 | exocytosis | 10734056 |
| Tgene | CCL5 | GO:0006954 | inflammatory response | 21147091 |
| Tgene | CCL5 | GO:0007159 | leukocyte cell-cell adhesion | 8558019 |
| Tgene | CCL5 | GO:0007186 | G protein-coupled receptor signaling pathway | 17001303|23979485 |
| Tgene | CCL5 | GO:0007267 | cell-cell signaling | 8558019 |
| Tgene | CCL5 | GO:0009636 | response to toxic substance | 10841574 |
| Tgene | CCL5 | GO:0010759 | positive regulation of macrophage chemotaxis | 16778803 |
| Tgene | CCL5 | GO:0010820 | positive regulation of T cell chemotaxis | 1699135|7544376|16778803|18337562 |
| Tgene | CCL5 | GO:0014068 | positive regulation of phosphatidylinositol 3-kinase signaling | 7544376 |
| Tgene | CCL5 | GO:0014911 | positive regulation of smooth muscle cell migration | 21297082 |
| Tgene | CCL5 | GO:0030335 | positive regulation of cell migration | 7545673 |
| Tgene | CCL5 | GO:0031328 | positive regulation of cellular biosynthetic process | 18337562 |
| Tgene | CCL5 | GO:0031584 | activation of phospholipase D activity | 9469451 |
| Tgene | CCL5 | GO:0031663 | lipopolysaccharide-mediated signaling pathway | 21147091 |
| Tgene | CCL5 | GO:0033634 | positive regulation of cell-cell adhesion mediated by integrin | 8558019 |
| Tgene | CCL5 | GO:0034112 | positive regulation of homotypic cell-cell adhesion | 10488085 |
| Tgene | CCL5 | GO:0042102 | positive regulation of T cell proliferation | 18832695 |
| Tgene | CCL5 | GO:0042119 | neutrophil activation | 10488085 |
| Tgene | CCL5 | GO:0042327 | positive regulation of phosphorylation | 18337562 |
| Tgene | CCL5 | GO:0042531 | positive regulation of tyrosine phosphorylation of STAT protein | 9417081 |
| Tgene | CCL5 | GO:0043922 | negative regulation by host of viral transcription | 10841574 |
| Tgene | CCL5 | GO:0045071 | negative regulation of viral genome replication | 10490959 |
| Tgene | CCL5 | GO:0045744 | negative regulation of G protein-coupled receptor signaling pathway | 10734056 |
| Tgene | CCL5 | GO:0045785 | positive regulation of cell adhesion | 10910894 |
| Tgene | CCL5 | GO:0048245 | eosinophil chemotaxis | 16778803 |
| Tgene | CCL5 | GO:0048661 | positive regulation of smooth muscle cell proliferation | 21297082 |
| Tgene | CCL5 | GO:0050796 | regulation of insulin secretion | 23979485 |
| Tgene | CCL5 | GO:0050863 | regulation of T cell activation | 10488085 |
| Tgene | CCL5 | GO:0051928 | positive regulation of calcium ion transport | 8699119 |
| Tgene | CCL5 | GO:0070098 | chemokine-mediated signaling pathway | 17001303 |
| Tgene | CCL5 | GO:0070233 | negative regulation of T cell apoptotic process | 10488085 |
| Tgene | CCL5 | GO:0070234 | positive regulation of T cell apoptotic process | 10488085 |
| Tgene | CCL5 | GO:0071407 | cellular response to organic cyclic compound | 21147091 |
| Tgene | CCL5 | GO:0090026 | positive regulation of monocyte chemotaxis | 1699135|19779041 |
| Tgene | CCL5 | GO:1901214 | regulation of neuron death | 17001303 |
| Tgene | CCL5 | GO:2000406 | positive regulation of T cell migration | 23620790 |
| Tgene | CCL5 | GO:2000503 | positive regulation of natural killer cell chemotaxis | 7545673 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:35478277/chr17:34199468) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here. |
| Fusion gene breakpoints across ACACA (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across CCL5 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Amino Acid Sequences |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000353139 | ACACA | chr17 | 35478277 | - | ENST00000293272 | CCL5 | chr17 | 34199468 | - | 7730 | 6756 | 461 | 6838 | 2125 |
| ENST00000353139 | ACACA | chr17 | 35478277 | - | ENST00000366113 | CCL5 | chr17 | 34199468 | - | 7730 | 6756 | 461 | 6838 | 2125 |
| ENST00000360679 | ACACA | chr17 | 35478277 | - | ENST00000293272 | CCL5 | chr17 | 34199468 | - | 7398 | 6424 | 297 | 6506 | 2069 |
| ENST00000360679 | ACACA | chr17 | 35478277 | - | ENST00000366113 | CCL5 | chr17 | 34199468 | - | 7398 | 6424 | 297 | 6506 | 2069 |
| ENST00000361253 | ACACA | chr17 | 35478277 | - | ENST00000293272 | CCL5 | chr17 | 34199468 | - | 1833 | 859 | 195 | 941 | 248 |
| ENST00000361253 | ACACA | chr17 | 35478277 | - | ENST00000366113 | CCL5 | chr17 | 34199468 | - | 1833 | 859 | 195 | 941 | 248 |
| ENST00000353139 | ACACA | chr17 | 35478276 | - | ENST00000293272 | CCL5 | chr17 | 34199468 | - | 7730 | 6756 | 461 | 6838 | 2125 |
| ENST00000353139 | ACACA | chr17 | 35478276 | - | ENST00000366113 | CCL5 | chr17 | 34199468 | - | 7730 | 6756 | 461 | 6838 | 2125 |
| ENST00000360679 | ACACA | chr17 | 35478276 | - | ENST00000293272 | CCL5 | chr17 | 34199468 | - | 7398 | 6424 | 297 | 6506 | 2069 |
| ENST00000360679 | ACACA | chr17 | 35478276 | - | ENST00000366113 | CCL5 | chr17 | 34199468 | - | 7398 | 6424 | 297 | 6506 | 2069 |
| ENST00000361253 | ACACA | chr17 | 35478276 | - | ENST00000293272 | CCL5 | chr17 | 34199468 | - | 1833 | 859 | 195 | 941 | 248 |
| ENST00000361253 | ACACA | chr17 | 35478276 | - | ENST00000366113 | CCL5 | chr17 | 34199468 | - | 1833 | 859 | 195 | 941 | 248 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000353139 | ENST00000293272 | ACACA | chr17 | 35478277 | - | CCL5 | chr17 | 34199468 | - | 0.001129216 | 0.9988708 |
| ENST00000353139 | ENST00000366113 | ACACA | chr17 | 35478277 | - | CCL5 | chr17 | 34199468 | - | 0.001129216 | 0.9988708 |
| ENST00000360679 | ENST00000293272 | ACACA | chr17 | 35478277 | - | CCL5 | chr17 | 34199468 | - | 0.001123946 | 0.99887604 |
| ENST00000360679 | ENST00000366113 | ACACA | chr17 | 35478277 | - | CCL5 | chr17 | 34199468 | - | 0.001123946 | 0.99887604 |
| ENST00000361253 | ENST00000293272 | ACACA | chr17 | 35478277 | - | CCL5 | chr17 | 34199468 | - | 0.06944496 | 0.9305551 |
| ENST00000361253 | ENST00000366113 | ACACA | chr17 | 35478277 | - | CCL5 | chr17 | 34199468 | - | 0.06944496 | 0.9305551 |
| ENST00000353139 | ENST00000293272 | ACACA | chr17 | 35478276 | - | CCL5 | chr17 | 34199468 | - | 0.001129216 | 0.9988708 |
| ENST00000353139 | ENST00000366113 | ACACA | chr17 | 35478276 | - | CCL5 | chr17 | 34199468 | - | 0.001129216 | 0.9988708 |
| ENST00000360679 | ENST00000293272 | ACACA | chr17 | 35478276 | - | CCL5 | chr17 | 34199468 | - | 0.001123946 | 0.99887604 |
| ENST00000360679 | ENST00000366113 | ACACA | chr17 | 35478276 | - | CCL5 | chr17 | 34199468 | - | 0.001123946 | 0.99887604 |
| ENST00000361253 | ENST00000293272 | ACACA | chr17 | 35478276 | - | CCL5 | chr17 | 34199468 | - | 0.06944496 | 0.9305551 |
| ENST00000361253 | ENST00000366113 | ACACA | chr17 | 35478276 | - | CCL5 | chr17 | 34199468 | - | 0.06944496 | 0.9305551 |
| Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones. |
Get the fusion protein sequences from here. |
| Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for ACACA-CCL5 |
| +/-13 AA sequence from the breakpoints of the fusion protein sequences. |
| Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
| ACACA | chr17 | 35478276 | CCL5 | chr17 | 34199468 | 6424 | 2042 | VFANWRGFSGGMKALSPERTAKCVPT |
| ACACA | chr17 | 35478276 | CCL5 | chr17 | 34199468 | 6756 | 2098 | VFANWRGFSGGMKALSPERTAKCVPT |
| ACACA | chr17 | 35478276 | CCL5 | chr17 | 34199468 | 859 | 221 | VFANWRGFSGGMKALSPERTAKCVPT |
| ACACA | chr17 | 35478277 | CCL5 | chr17 | 34199468 | 6424 | 2042 | VFANWRGFSGGMKALSPERTAKCVPT |
| ACACA | chr17 | 35478277 | CCL5 | chr17 | 34199468 | 6756 | 2098 | VFANWRGFSGGMKALSPERTAKCVPT |
| ACACA | chr17 | 35478277 | CCL5 | chr17 | 34199468 | 859 | 221 | VFANWRGFSGGMKALSPERTAKCVPT |
Top |
Potential FusionNeoAntigen Information of ACACA-CCL5 in HLA I |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| ACACA-CCL5_35478276_34199468.msa |
| Potential FusionNeoAntigen Information * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | HLA-A31:02 | GMKALSPER | 0.8888 | 0.5043 | 10 | 19 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | HLA-A30:08 | KALSPERTAK | 0.9942 | 0.7528 | 12 | 22 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | HLA-B39:06 | WRGFSGGMKA | 0.9494 | 0.976 | 4 | 14 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | HLA-B27:14 | WRGFSGGMKA | 0.996 | 0.8371 | 4 | 14 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | HLA-B73:01 | WRGFSGGMKA | 0.9902 | 0.9266 | 4 | 14 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | HLA-C14:02 | GFSGGMKAL | 0.0481 | 0.9809 | 6 | 15 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | HLA-C14:03 | GFSGGMKAL | 0.0481 | 0.9809 | 6 | 15 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | HLA-A30:01 | KALSPERTAK | 0.9942 | 0.8546 | 12 | 22 |
Top |
Potential FusionNeoAntigen Information of ACACA-CCL5 in HLA II |
| Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific. |
| ACACA-CCL5_35478276_34199468.msa |
| Potential FusionNeoAntigen Information * We used NetMHCIIpan v4.1 (%rank<0.5). |
| Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | DRB1-0102 | FSGGMKALSPERTAK | 7 | 22 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | DRB1-0123 | FSGGMKALSPERTAK | 7 | 22 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | DRB1-1001 | FSGGMKALSPERTAK | 7 | 22 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | DRB1-1002 | FSGGMKALSPERTAK | 7 | 22 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | DRB1-1002 | SGGMKALSPERTAKC | 8 | 23 |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 | DRB1-1003 | FSGGMKALSPERTAK | 7 | 22 |
Top |
Fusion breakpoint peptide structures of ACACA-CCL5 |
| 3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
| File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
| 2786 | GFSGGMKALSPERT | ACACA | CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6756 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ACACA-CCL5 |
| Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens * We used Glide to predict the interaction between HLAs and neoantigens. |
| HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
| HLA-B14:02 | 3BVN | 2786 | GFSGGMKALSPERT | -5.49802 | -5.50512 |
| HLA-B52:01 | 3W39 | 2786 | GFSGGMKALSPERT | -4.88484 | -4.89194 |
| HLA-A24:02 | 5HGA | 2786 | GFSGGMKALSPERT | -9.7287 | -9.7358 |
| HLA-B44:05 | 3DX8 | 2786 | GFSGGMKALSPERT | -6.55078 | -6.55788 |
| HLA-A02:01 | 6TDR | 2786 | GFSGGMKALSPERT | -1.02296 | -1.03006 |
Top |
Vaccine Design for the FusionNeoAntigens of ACACA-CCL5 |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 10 | 19 | GMKALSPER | GAATGAAAGCTTTGTCACCCGAAAGAA |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 12 | 22 | KALSPERTAK | AAGCTTTGTCACCCGAAAGAACCGCCAAGT |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 4 | 14 | WRGFSGGMKA | GGAGAGGCTTCTCTGGTGGAATGAAAGCTT |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 6 | 15 | GFSGGMKAL | GCTTCTCTGGTGGAATGAAAGCTTTGT |
| mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs. |
| Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 7 | 22 | FSGGMKALSPERTAK | TCTCTGGTGGAATGAAAGCTTTGTCACCCGAAAGAACCGCCAAGT |
| ACACA-CCL5 | chr17 | 35478276 | chr17 | 34199468 | 8 | 23 | SGGMKALSPERTAKC | CTGGTGGAATGAAAGCTTTGTCACCCGAAAGAACCGCCAAGTGTG |
Top |
Information of the samples that have these potential fusion neoantigens of ACACA-CCL5 |
| These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens. |
| Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
| SARC | ACACA-CCL5 | chr17 | 35478276 | ENST00000353139 | chr17 | 34199468 | ENST00000293272 | TCGA-IE-A3OV |
Top |
Potential target of CAR-T therapy development for ACACA-CCL5 |
| Predicted 3D structure. We used RoseTTAFold. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features * Minus value of BPloci means that the break point is located before the CDS. |
| - In-frame and retained 'Transmembrane'. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Subcellular localization prediction of the transmembrane domain retained fusion proteins * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
| Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to ACACA-CCL5 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to ACACA-CCL5 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2023-PresentThe University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information
Campus Carry|Site Policies